A new study reveals that obesity-related changes in body fat can disrupt brain signals and immune function, potentially worsening Alzheimer's disease.
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'
Young adults in India are increasingly grappling with high blood pressure, a condition once thought to affect mainly the older demographics. Cardiologists point to sedentary lifestyles, obesity, chronic stress and unhealthy diets as primary drivers of this silent epidemic.
'Control your A, B, C and D.' 'A is A1C, keep your A1C below 7 per cent.' 'B is blood pressure, so keep your blood pressure at 130/ 80 or at least below 140/ 90.' 'C is cholesterol. The bad cholesterol is the LDL cholesterol, and it should be kept below 100, preferably below 70 or 50.' 'D is discipline like diet, exercise, sleep, no smoking, etc.' 'People with diabetes who follow A, B, C and D can live up to even 100 years of age without any complications.'
Over the past year, the sale of injectable GLP-1 agonists (used to treat type 2 diabetes and obesity) such as Mounjaro, Wegovy and Ozempic have surged a whopping 218 per cent.
From what goes on your plate to how long someone sits with a laptop on their lap, seemingly harmless habits can make a big difference, warns says Dr Aakil Khan, consultant and urologist at KIMS Hospitals, Thane.
Biocon Limited has launched its GLP-1 peptide, liraglutide, for the treatment of diabetes and obesity in the Netherlands, as the biopharmaceutical firm positions itself as a global player in the fast-growing diabetes and obesity market currently dominated by the likes of Novo Nordisk and Eli Lilly.
The semaglutide patent expiry next year could unleash a wave of generic versions from Indian drugmakers, with prices expected to go lower -- at least 80 per cent.
For years, creatine has been associated with bodybuilders looking to bulk up. But emerging research is changing that perception.
Gynaecologists are noticing a gradual rise in POI cases, with a few women under 40 being diagnosed every month.
'Don't chase unrealistic expectations or compare yourself to social media transformations.' 'Focus on your health first, not just the number on the scale before the wedding.'
Emcure Pharmaceuticals on Monday said it saw Poviztra, its newly launched semaglutide brand, as a "long-term" opportunity in India's fast-evolving obesity and cardiometabolic therapy market, even as price competition in the glucagon-like peptide-1 (GLP-1) segment intensified.
PCOS is being renamed PMOS. Dr Anagha Menon breaks down why the one alphabet change matters and how it affects the diagnosis of this condition for so many women.
'...would obesity still be a global epidemic?'
Rising mercury levels in Madhya Pradesh are causing sleepless nights for residents as minimum temperatures remain high. Doctors report an increase in sleep-related issues, allergies, and fatigue due to the heat.
Rising mercury levels in Madhya Pradesh are causing discomfort for residents as night temperatures fail to provide relief, disrupting sleep patterns and daily routines.
'The unregulated marketing has to stop. People are getting recommendations for this from gym trainers, from marriage counsellors -- that is simply unacceptable.' ''There are many ways to lose weight -- eat less, fast, exercise, eat healthy. That is how you lose weight.'
The fast-growing GLP-1 market, propelled by lower-cost generics following patent expiry, is widening availability beyond patients with obesity and diabetes -- but also driving unsupervised, appearance-led demand, according to doctors.
'Refined carbohydrates are the quiet troublemaker in our diet.' 'We eat plenty of calories, but not enough nutrition.'
Biocon is actively seeking in-licensing opportunities to expand its biosimilars portfolio, focusing on products that complement existing therapy areas, as the company shifts to a 'consolidate' phase with a strong emphasis on improving capacity utilisation, expanding margins, and driving return on capital employed.
Authorities in Gurugram have uncovered a racket involved in the manufacturing and sale of fake Mounjaro (tirzepatide) injections, used for treating diabetes and obesity. Two people have been arrested, and a nationwide alert has been issued to trace counterfeit batches.
Pharmaceutical major Cipla reported a 3 per cent year-on-year decline in March quarter revenue to Rs 6,541 crore, with net profit falling 55 per cent to Rs 554.6 crore, missing consensus estimates. Despite strong growth in India and Africa, a significant decline in North American sales impacted overall performance, with the company now focusing on new product launches and regulatory filings to drive future gains.
Young adults show alarming NCD trends, with high rates of obesity, prediabetes, and abnormal cholesterol levels.
An independent think tank on policing has called for a multi-agency investigation into the recent unearthing of a spurious Mounjaro (tirzepatide) injection manufacturing racket in Gurugram, offering free-of-cost forensic expertise.
The number of Indian obese adults increased from 5.76 million in 1991 to 46.78 million in 2021; it is poised to reach 173.73 million by 2050.
The Union health ministry is urging all ministries and departments to display 'oil and sugar boards' in common areas to raise awareness about hidden fats and sugars in everyday foods and promote healthier lifestyles.
'In all these years of rupee depreciation, of rising oil prices, of inflation caused by import dependence, not one leader had the courage to look the people in the eye and say: Please do this for your country.'
Inspections conducted across 49 entities including pharmacies, wholesalers, and clinics to detect violations and misleading marketing practices.
A Swedish study reveals that individuals born with low birth weight face a significantly elevated risk of stroke in early adulthood, regardless of their BMI or gestational age.
'Infertility and reproductive health challenges, much like other chronic conditions, are rising globally.'
'Weight loss drugs can be life changing but are not without risks,' says Dr Vishnu Radhakrishnan as he explains the truth behind Ozempic and Mounjaro.
While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
The Central Board of Secondary Education (CBSE) has directed schools to set up dedicated 'Sugar Boards' to raise awareness about sugar consumption and combat childhood obesity. Experts hail the initiative as a significant step towards promoting healthier dietary habits among students and families. The boards will display information on the sugar content in common snacks, drinks, and meals, helping children make informed choices. This move comes as data reveals alarmingly high sugar intake among Indian children, exceeding the World Health Organization's recommended limits.
Prime Minister Narendra Modi, in his monthly 'Mann Ki Baat' radio broadcast, urged people to reduce their oil intake by 10% as a step towards fighting obesity. He highlighted the rising obesity rates in India and globally, emphasizing the need for healthier lifestyles. Modi also shared messages from Olympic medalist Neeraj Chopra and boxer Nikhat Zareen, who urged people to adopt healthy habits and avoid fried food. Cardiac surgeon Dr. Devi Shetty highlighted the medical seriousness of obesity and linked it to excessive carbohydrate intake and oil consumption. Modi concluded by challenging 10 people to reduce their oil intake and pass the challenge on to 10 others.
Olympic medallists Manu Bhaker and Mirabai Chanu have joined Prime Minister Narendra Modi's initiative to combat obesity, emphasizing the importance of healthy lifestyle choices.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.
A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.
